Pediococcus acidilactici GOLDGUT-PA0755 for Ulcerative Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis are inadequate, leading to immune tolerance and liver injury, and there is a need for more effective therapeutic agents that can prevent and treat the condition without causing these complications.
Innovation Solution
The use of Pediococcus acidilactici GOLDGUT-PA0755, a specific strain of bacteria, which is effective in relieving symptoms of ulcerative colitis by reducing weight loss, colon length reduction, DAI score, serum inflammatory factors, and restoring intestinal barriers, thereby inhibiting inflammation and repairing the intestinal mucosa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs (hormone medicines, 5-aminosalicylic acid derivatives, biological preparations) are used for treating ulcerative colitis, then inflammation is suppressed and symptoms are alleviated, but long-term use causes immune tolerance and liver injury
Solution Approach 1:
The patent introduces Pediococcus acidilactici GOLDGUT-PA0755 as a microbial intermediary that mediates the treatment of ulcerative colitis. Instead of directly administering conventional drugs that cause harm, the probiotic strain acts as a mediator to restore intestinal flora balance, reduce inflammation, and repair intestinal barriers, thereby achieving therapeutic effects without the harmful side effects of traditional medications
Solution Approach 2:
The patent employs a biologically active probiotic strain that can be administered orally and transiently performs its therapeutic function. The Pediococcus acidilactici GOLDGUT-PA0755 strain acts as a temporary therapeutic agent that colonizes the intestine briefly to exert its anti-inflammatory and barrier-repairing effects, then is naturally eliminated, avoiding long-term accumulation and chronic toxicity associated with conventional drugs
2Ease of operation
If conventional drugs are used for symptom alleviation, then inflammation is reduced, but the treatment does not address the root cause and leads to dependency
Solution Approach 1:
The patent applies preliminary action by administering Pediococcus acidilactici GOLDGUT-PA0755 to preemptively restore intestinal flora balance before severe inflammation and damage occur. The probiotic strain proactively colonizes the intestine, prevents dysbacteriosis, and maintains intestinal barrier integrity, thereby preventing the development of ulcerative colitis rather than merely treating symptoms after they manifest
Solution Approach 2:
The patent enables self-service by introducing a probiotic strain that autonomously performs multiple therapeutic functions within the intestine. Pediococcus acidilactici GOLDGUT-PA0755 self-regulates inflammation, self-repairs intestinal barriers, and self-maintains flora balance without requiring continuous external drug intervention, thereby providing sustainable long-term therapeutic effects
Data Source
AI summary
A strain of Pediococcus acidilactici with a function of treating ulcerative colitis and its application are disclosed. The disclosure provides a strain of Pediococcus acidilactici GOLDGUT-PA0755, which can relieve ulcerative colitis, inhibit inflammation and repair intestinal barriers, specifically in: relieving the weight loss, colon length ratio reduction and DAI score increase caused by DSS of ulcerative colitis model mice, reducing the rise of the serum inflammatory factor level and the rise of the ratio of the inflammatory factor to the anti-inflammatory factor caused by DSS of ulcerative colitis model mice, recovering the injury of colonic mucosa caused by DSS of ulcerative colitis model mice, reducing the decrease of anti-inflammatory factors and the increase of the ratio of the inflammatory factor to the anti-inflammatory factor caused by the DSS of PBMC cells, and restoring the content of the tight junctional protein ZO-1 in inflammation injury model of monolayer epithelium.